Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis.
Mingxia JiangYue ChaiJiaxuan LiuMaiyue HeYipeng WangXue YangZeyu XingMengqi ZhangShihan ZhouFei MaJiayu WangPeng YuanBinghe XuQiao LiPublished in: BMC cancer (2024)
NCT05749016 (registration date: Nov 01, 2021).